- Home
- DRUG vs PRME Comparison
DRUG vs PRME Comparison
Compare DRUG & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- PRME
- Stock Information
- Founded
- DRUG 2019
- PRME 2019
- Country
- DRUG United States
- PRME United States
- Employees
- DRUG N/A
- PRME N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- PRME Medicinal Chemicals and Botanical Products
- Sector
- DRUG Health Care
- PRME Health Care
- Exchange
- DRUG Nasdaq
- PRME Nasdaq
- Market Cap
- DRUG 199.7M
- PRME 191.7M
- IPO Year
- DRUG N/A
- PRME 2022
- Fundamental
- Price
- DRUG $25.41
- PRME $4.27
- Analyst Decision
- DRUG Strong Buy
- PRME Buy
- Analyst Count
- DRUG 7
- PRME 6
- Target Price
- DRUG $83.25
- PRME $9.38
- AVG Volume (30 Days)
- DRUG 60.0K
- PRME 5.0M
- Earning Date
- DRUG 08-13-2025
- PRME 08-04-2025
- Dividend Yield
- DRUG N/A
- PRME N/A
- EPS Growth
- DRUG N/A
- PRME N/A
- EPS
- DRUG N/A
- PRME N/A
- Revenue
- DRUG N/A
- PRME $3,846,000.00
- Revenue This Year
- DRUG N/A
- PRME $104.12
- Revenue Next Year
- DRUG N/A
- PRME $108.24
- P/E Ratio
- DRUG N/A
- PRME N/A
- Revenue Growth
- DRUG N/A
- PRME 550.76
- 52 Week Low
- DRUG $0.93
- PRME $1.11
- 52 Week High
- DRUG $79.02
- PRME $6.75
- Technical
- Relative Strength Index (RSI)
- DRUG 43.34
- PRME 80.29
- Support Level
- DRUG $26.09
- PRME $2.28
- Resistance Level
- DRUG $27.50
- PRME $4.83
- Average True Range (ATR)
- DRUG 1.95
- PRME 0.46
- MACD
- DRUG 0.12
- PRME 0.21
- Stochastic Oscillator
- DRUG 44.62
- PRME 84.52
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.